News and analysis on diagnostic technologies and applications.
The firm reissued its full-year guidance and said it expects to sell 60 instruments in the US for the remainder of the year.
The London-based firm hopes to also show the clinical utility of its KidneyIntelX assay for predicting the risk of the patients' progressive kidney decline.
Use of the test, which detects viral nucleic acid in upper respiratory specimens and bronchoalveolar lavage, is limited to George Washington University.
The immune sequencing firm also provided an update on the development of its ImmunoSeq Dx clinical product for detecting prior infection with SARS-CoV-2.
The skin cancer diagnostics company said it delivered 19 percent fewer DecisionDx-Melanoma test results in Q2 2020 than in the previous year's second quarter.
